Research Reference
Oxytocin
FDA-approved neuropeptide hormone for labor induction and bonding
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Oxytocin is an FDA-approved neuropeptide hormone used medically for labor induction and postpartum bleeding, and researched for social bonding.
Dosing Reference
Reconstitution
Add 5 mL bacteriostatic water to the 5 mg vial. Resulting concentration: 1 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 24 mcg | 2.4 units | 0.02 mL | Intranasal, 1–3x dailyCommunity social/bonding protocol |
| 40 mcg | 4 units | 0.04 mL | Intranasal, 1–3x dailyCommunity higher dose |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Oxytocin is FDA-approved (Pitocin, Syntocinon) for obstetric use as an intravenous infusion; an intranasal spray (Syntocinon) was previously FDA-approved for lactation support and withdrawn for commercial (not safety) reasons. Compounded research-peptide intranasal or injectable forms are not FDA-approved.
For a compounded 5 mg vial reconstituted with 5 mL, the concentration is 1 mg/mL; intranasal doses are metered by spray pump (typically ~0.1 mL = 100 mcg per spray). Store per manufacturer directions; compounded forms are not FDA-approved.
Cycling Protocol
Community protocols describe intranasal oxytocin used 1–3 times daily for 2–4 weeks, sometimes cycled. No standardized cycle is established for off-label use; oxytocin is FDA-approved only for obstetric/lactation indications, and compounded forms are not FDA-approved.
Routes of Administration
Intranasal (community/off-label): Administered as a nasal spray for off-label social/bonding use.
Intravenous (FDA-approved): Pitocin IV for labor induction/augmentation and postpartum hemorrhage — hospital use only.
Intramuscular (FDA-approved): Postpartum use for hemorrhage control.
Compounded intranasal/injectable forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Bonding Stack | Oxytocin + relationship/therapy context | Community social-bonding protocol (not established) |
Off-label oxytocin use is community extrapolation. Oxytocin is FDA-approved only for obstetric/lactation indications. Compounded forms are not FDA-approved.
Side Effects & Safety
- Nasal irritation — possible with intranasal use
- Headache, dizziness — occasionally reported
- Water intoxication / hyponatremia — risk with high-dose IV oxytocin (obstetric use); rare with intranasal
- Uterine hyperstimulation — risk in obstetric IV use
- Allergic reactions — rare
Oxytocin (Pitocin/Syntocinon) is FDA-approved for obstetric/lactation use. Compounded research-peptide intranasal forms are not FDA-approved.
Research Basis
Oxytocin is a naturally occurring neuropeptide hormone produced in the hypothalamus and released by the posterior pituitary, FDA-approved (Pitocin, Syntocinon).
Mechanism: Acts on oxytocin receptors in the uterus (stimulating contraction) and mammary glands (milk ejection), and centrally on social bonding, trust, and reward pathways.
Clinical evidence: FDA-approved for labor induction/augmentation, postpartum hemorrhage control, and lactation support. Off-label intranasal use for social bonding, anxiety, and autism-spectrum contexts is studied but not FDA-approved.
FDA-approved for obstetric/lactation use. Off-label intranasal use is not FDA-approved. Compounded research-peptide forms are not FDA-approved.